Accuray traded at $2.80 this Friday November 13th, decreasing $0.28 or 9.09 percent since the previous trading session. Looking back, over the last four weeks, Accuray lost 1,499.09 percent. Over the last 12 months, its price rose by 169.23 percent. Looking ahead, we forecast Accuray to be priced at 2.74 by the end of this quarter and at 2.56 in one year, according to Trading Economics global macro models projections and analysts expectations.
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The Company's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.